Abstract:Highlights • This summary covers the key sources of immune cells and the engineering methods used for adoptive cellular immunotherapy. • The synergistic mechanisms of combining adoptive immune cells with various treatments are illustrated. • The current challenges and prospects of adoptive immune cell immunotherapy with multi-model treatment for clinical applications are discussed. Adoptive immunotherapy, notably involving chimeric antigen receptor (CAR)-T cells, has obtained Food and Drug Administration (FDA) approval as a treatment for various hematological malignancies, demonstrating promising preclinical efficacy against cancers. However, the intricate and resource-intensive autologous cell processing, encompassing collection, expansion, engineering, isolation, and administration, hamper the efficacy of this therapeutic modality. Furthermore, conventional CAR T therapy is presently confined to addressing solid tumors due to impediments posed by physical barriers, the potential for cytokine release syndrome, and cellular exhaustion induced by the immunosuppressive and heterogeneous tumor microenvironment. Consequently, a strategic integration of adoptive immunotherapy with synergistic multimodal treatments, such as chemotherapy, radiotherapy, and vaccine therapy etc., emerges as a pivotal approach to surmount these inherent challenges. This collaborative strategy holds the key to addressing the limitations delineated above, thereby facilitating the realization of more precise personalized therapies characterized by heightened therapeutic efficacy. Such synergistic strategy not only serves to mitigate the constraints associated with adoptive immunotherapy but also fosters enhanced clinical applicability, thereby advancing the frontiers of therapeutic precision and effectiveness. Graphical abstract Download: Download high-res image (513KB) Download: Download full-size image

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy

Efficacy and Safety of Adoptive Immunotherapy Using Anti-Cd19 Chimeric Antigen Receptor Transduced T-cells: a Systematic Review of Phase I Clinical Trials.

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

In vivo engineering chimeric antigen receptor immune cells with emerging nanotechnologies

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers

Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

The potential and promise for clinical application of adoptive T cell therapy in cancer

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

Current Clinical Application of the CAR-T Cell Therapy

Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors

Adoptive Immunotherapy beyond CAR T-Cells

Synthetic immunology: T-cell engineering and adoptive immunotherapy